| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
9.23(B) |
| Last
Volume: |
2,566,045 |
Avg
Vol: |
1,923,197 |
| 52
Week Range: |
$54.15 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
103,519 |
108,398 |
168,494 |
290,334 |
| Total Sell Value |
$6,219,303 |
$6,570,910 |
$11,439,131 |
$18,676,003 |
| Total People Sold |
10 |
10 |
11 |
11 |
| Total Sell Transactions |
49 |
52 |
62 |
100 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Condella Sarah |
EVP, Human Resources |
• – – |
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,248 |
72,737 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,374 |
1,234,731 |
|
- |
|
| Baranick Brian |
Gen. Mgr., Precision Oncology |
• – – |
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,729 |
9,721 |
|
- |
|
| Coward D Scott |
Director |
– • – |
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,248 |
43,828 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,112 |
5,196 |
|
- |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,248 |
9,736 |
|
- |
|
| Herriott James |
General Counsel |
• – – |
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
864 |
7,358 |
|
- |
|
| Coward D Scott |
Director |
– • – |
2024-02-15 |
4 |
AS |
$61.43 |
$84,528 |
D/D |
(1,376) |
41,580 |
|
-12% |
|
| Herriott James |
General Counsel |
• – – |
2024-02-15 |
4 |
AS |
$61.43 |
$25,862 |
D/D |
(421) |
6,494 |
|
-12% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2024-02-15 |
4 |
AS |
$61.43 |
$115,980 |
D/D |
(1,888) |
2,084 |
|
-12% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2024-02-15 |
4 |
AS |
$61.43 |
$59,280 |
D/D |
(965) |
70,489 |
|
-12% |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2024-02-15 |
4 |
AS |
$61.43 |
$59,341 |
D/D |
(966) |
7,488 |
|
-12% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2024-02-15 |
4 |
AS |
$61.43 |
$908,611 |
D/D |
(14,791) |
1,224,357 |
|
-12% |
|
| Coward D Scott |
Director |
– • – |
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,972 |
42,956 |
|
- |
|
| Herriott James |
General Counsel |
• – – |
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
883 |
6,915 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,972 |
3,972 |
|
- |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,031 |
71,454 |
|
- |
|
| Orville Jacob A |
General Manager, Screening |
• – – |
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,031 |
8,454 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,133 |
1,239,148 |
|
- |
|
| Baranick Brian |
Gen. Mgr., Precision Oncology |
• – – |
2024-01-02 |
4 |
AS |
$73.50 |
$64,607 |
D/D |
(879) |
7,992 |
|
-27% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2024-01-02 |
4 |
AS |
$73.50 |
$147,000 |
D/D |
(2,000) |
69,423 |
|
-27% |
|
| Condella Sarah |
EVP, Human Resources |
• – – |
2023-12-14 |
4 |
AS |
$70.00 |
$140,000 |
D/D |
(2,000) |
71,423 |
|
-13% |
|
| Herriott James |
General Counsel |
• – – |
2023-10-31 |
4 |
A |
$30.02 |
$2,041 |
D/D |
68 |
6,032 |
|
- |
|
| Scannell Timothy J |
Director |
– • – |
2023-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,694 |
5,694 |
|
- |
|
| Cunningham Everett |
Chief Commercial Officer |
• – – |
2023-10-12 |
4 |
AS |
$66.49 |
$864,835 |
D/D |
(13,007) |
37,909 |
|
-8% |
|
957 Records found
|
|
Page 4 of 39 |
|
|
1.39 (2.61%) 
